Oncopeptides presented at Aktiespararna Life Science 2025
January 30, 2025 – Oncopeptides’ CEO Sofia Heigis recently presented the company at the Aktiespararna event themed Life Science.
Oncopeptides’ Pepaxti formally approved for full reimbursement in Italy
January 27, 2025 – Oncopeptides today announces that the positive reimbursement decision for its drug Pepaxti (melflufen) has been published in the Italian Official Journal (“IOJ”, It.: Gazetta Ufficiale). This marks the final regulatory step for the drug’s upcoming commercialization in Italy, confirming Oncopeptides’ expectation of first sales during H1, 2025.